

Highly Specialised Technologies (HST) Evaluation Committee Interests Register
Topic: Targeted-release budesonide for treating primary IgA nephropathy [ID1434]
Publication Date: 20/12/2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Professor Jonathan Barratt	Clinical Expert	Direct & Indirect financial	<p>Professor Barratt declared the following:</p> <p>I provide independent consulting advice to Calliditas and Britannia Pharmaceuticals Ltd/ STADA Arzneimittel AG.</p> <p>I have delivered Educational Symposia sponsored by Calliditas and Britannia Pharmaceuticals Ltd/ STADA Arzneimittel AG at international conferences.</p> <p>I have received research funding from Calliditas for biomarker studies using samples from the NEFIGAN and NeflgArd studies</p>	06/04/2023	It was agreed that his declarations would not prevent Professor Barratt from providing expert advice to the committee.
Dr Chee Kay Cheung	Clinical Expert	Direct financial & non-financial	<p>Dr Cheung declared the following:</p> <p>I report having a consultancy agreement with Calliditas Therapeutics, having participated on</p>	28/06/2023	It was agreed that his declarations would not prevent Dr Cheung from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>an advisory board, delivering a sponsored symposium and developing educational material for Calliditas, who have developed targeted-release budesonide. I have delivered a sponsored symposium for Stada Pharma regarding targeted-release budesonide.</p> <p>Other interests:</p> <p>Consultancy agreements: George Clinical, Vera Therapeutics, Alpine Immune Sciences</p> <p>Advisory boards: Travers Therapeutics, CSL Vifor, Novartis</p> <p>Research funding: GlaxoSmithKline, Travers Therapeutics</p>		providing expert advice to the committee.